Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Erasca Inc.

PharmaDeviceNews Erasca Inc.

A representative image illustrating Erasca, Inc.’s ERAS-0015 pancreatic cancer program as the FDA grants Fast Track designation following an encouraging 57% preliminary response signal in KRAS-mutant pancreatic cancer and the company prepares for registration-focused development.

Pharma & Biotech

ERAS-0015 gets FDA Fast Track status after 57% response signal in pancreatic cancer

by Soujanya Ravi
August 24, 2026
0 Comments

ERAS-0015 wins FDA Fast Track status after a 57% early response signal in KRAS pancreatic cancer as Erasca prepares three registration-focused trials.

Read More

Latest news and features

CTX310 delivers one-year lipid reductions as CRISPR Therapeutics advances in vivo cardiovascular editing
Aficamten clears pivotal Phase 3 test in non-obstructive HCM as Cytokinetics prepares FDA filing
Abbott Libre Duo watches a diabetes danger signal CGMs have historically missed
Gilead Sciences’ Bixlenvo turns up to 11 HIV pills into one, but who benefits most?
A once-daily pill just changed dermatomyositis treatment. What the FDA’s LISRAYA approval means
Why destroying IgG faster can treat myasthenia gravis without depleting B cells
Cytrellis launches ellacor in Australia as Micro-Coring expands from facial wrinkles to body resurfacing
Hyperfine publishes 125-patient portable MRI study as outpatient Swoop use passes 3,000 scans
Nicox reaches FDA review with NCX 470 after two Phase 3 trials beat glaucoma pressure baseline
Lytix moves ruxotemitide toward registrational melanoma trial after FDA backs EFS endpoint
Why atrial fibrillation ablation is moving from heat and freezing to pulsed electric fields
New soquelitinib data support Corvus Pharmaceuticals’ pivotal push in relapsed T-cell lymphoma

POPULAR NEWS

Representative image of a clinician reviewing skeletal imaging, illustrating Mirum Pharmaceuticals and Incyte’s zilurgisertib Phase 2 progress in fibrodysplasia ossificans progressiva and the rare disease treatment questions facing regulators.

Pharma & Biotech

Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment

June 15, 2026

Niagen Bioscience’s NB4168 has secured U.S. FDA Rare Pediatric Disease and European orphan designations as the company advances the experimental ataxia telangiectasia therapy toward human trials. Representative image.

Pharma & Biotech

Niagen wins twin rare-disease designations, but can NB4168 turn nicotinamide riboside evidence into a medicine?

July 14, 2026

Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.

Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

June 9, 2026

Latest business and industry news

Critical Metals advances European Lithium takeover as $835m mining deal moves toward court review
Norway mourns King Harald V as Haakon VIII takes throne after historic 35-year reign
FIFA crisis escalates as UEFA prepares criminal complaint against Gianni Infantino over $4.2bn World Cup deal
Frontline revenue nearly doubles to $943m as Middle East disruption lifts tanker earnings
Arrow Exploration Q2 revenue jumps 116% as Colombia production reaches 4,902boepd

TAGS

clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immuno-oncology immunotherapy Inc. Johnson & Johnson medical devices oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration US Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.